These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 10770783)

  • 1. Bioavailability of once- and twice-daily regimens of didanosine in human immunodeficiency virus-infected children.
    Abreu T; Plaisance K; Rexroad V; Nogueira S; Oliveira RH; Evangelista LA; Rangel R; Silva IS; Knupp C; Lambert JS
    Antimicrob Agents Chemother; 2000 May; 44(5):1375-6. PubMed ID: 10770783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapy.
    Fletcher CV; Brundage RC; Remmel RP; Page LM; Weller D; Calles NR; Simon C; Kline MW
    Antimicrob Agents Chemother; 2000 Apr; 44(4):1029-34. PubMed ID: 10722507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Didanosine population pharmacokinetics in West African human immunodeficiency virus-infected children administered once-daily tablets in relation to efficacy after one year of treatment.
    Hirt D; Bardin C; Diagbouga S; Nacro B; Hien H; Zoure E; Rouet F; Ouiminga A; Urien S; Foulongne V; Van De Perre P; Tréluyer JM; Msellati P
    Antimicrob Agents Chemother; 2009 Oct; 53(10):4399-406. PubMed ID: 19581461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Penetration of didanosine in semen of HIV-1-infected men.
    Cruciani M; Liuzzi G; Chirianni A; Audagnotto S; Bonora S; Di Biagio A; Sinicco A; Bassetti M; Gatti G
    J Antimicrob Chemother; 2006 Jun; 57(6):1244-7. PubMed ID: 16556633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of food and pharmacokinetic variability on didanosine systemic exposure in HIV-infected children. Pediatric AIDS Clinical Trials Group Protocol 144 Study Team.
    Stevens RC; Rodman JH; Yong FH; Carey V; Knupp CA; Frenkel LM
    AIDS Res Hum Retroviruses; 2000 Mar; 16(5):415-21. PubMed ID: 10772527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Didanosine once daily: potential for expanded use.
    Pollard RB
    AIDS; 2000 Nov; 14(16):2421-8. PubMed ID: 11101051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel pharmacokinetic approach to predict virologic failure in HIV-1-infected paediatric patients.
    Bouazza N; Tréluyer JM; Msellati P; Van de Perre P; Diagbouga S; Nacro B; Hien H; Zoure E; Rouet F; Ouiminga A; Blanche S; Hirt D; Urien S
    AIDS; 2013 Mar; 27(5):761-8. PubMed ID: 23719348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of stavudine and didanosine coadministered with nelfinavir in human immunodeficiency virus-exposed neonates.
    Rongkavilit C; Thaithumyanon P; Chuenyam T; Damle BD; Limpongsanurak S; Boonrod C; Srigritsanapol A; Hassink EA; Hoetelmans RM; Cooper DA; Lange JM; Ruxrungtham K; Phanuphak P
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3585-90. PubMed ID: 11709344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Didanosine once daily: an overview.
    Youle M
    Antivir Ther; 1998; 3 Suppl 4():35-7. PubMed ID: 10723507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403.
    King JR; Nachman S; Yogev R; Hodge J; Aldrovandi G; Hughes MD; Chen J; Wiznia A; Damle B; Acosta EP
    Pediatr Infect Dis J; 2005 Oct; 24(10):880-5. PubMed ID: 16220085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Once versus twice daily administration of didanosine in children with symptomatic HIV-associated disease who were intolerant to or clinically deteriorated on zidovudine. The Italian Pediatric Collaborative Study Group on Didanosine.
    Marchisio P; Principi N; Gabiano C; Galli L; Gattinara GC; Caselli D; Zuccotti G; La Regina A; Paga C
    Antivir Ther; 1997 Jan; 2(1):47-55. PubMed ID: 11322266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nevirapine plus didanosine: once or twice daily combination?
    van Heeswijk RP; Veldkamp AI; Mulder JW; Meenhorst PL; Wit FW; Reiss P; Lange JM; Kwakkelstein MO; Beijnen JH; Hoetelmans RM
    J Acquir Immune Defic Syndr; 2000 Sep; 25(1):93-5. PubMed ID: 11064511
    [No Abstract]   [Full Text] [Related]  

  • 13. Lack of absorption of didanosine after rectal administration in human immunodeficiency virus-infected patients.
    Wintergerst U; Rolinski B; Sölder B; Bogner JR; Wolf E; Jäger H; Roscher AA; Belohradsky BH
    Antimicrob Agents Chemother; 1999 Mar; 43(3):699-701. PubMed ID: 10049294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of once and twice daily dosing of didanosine in combination with stavudine for the treatment of HIV-1 infection. AI 454-146 Team.
    Monno L; Cargnel A; Soranzo ML; Chirianni A; Ferraro T; Di Stefano M; Angarano G
    Antivir Ther; 1999; 4(4):195-202. PubMed ID: 10723498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Didanosine: an updated review of its use in HIV infection.
    Perry CM; Noble S
    Drugs; 1999 Dec; 58(6):1099-135. PubMed ID: 10651392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients.
    Pruvost A; Negredo E; Benech H; Theodoro F; Puig J; Grau E; García E; Moltó J; Grassi J; Clotet B
    Antimicrob Agents Chemother; 2005 May; 49(5):1907-14. PubMed ID: 15855513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in children infected with the human immunodeficiency virus.
    Kline MW; Fletcher CV; Harris AT; Evans KD; Brundage RC; Remmel RP; Calles NR; Kirkpatrick SB; Simon C
    J Pediatr; 1998 Mar; 132(3 Pt 1):543-6. PubMed ID: 9544920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Didanosine reduces atevirdine absorption in subjects with human immunodeficiency virus infections.
    Morse GD; Fischl MA; Shelton MJ; Borin MT; Driver MR; DeRemer M; Lee K; Wajszczuk CP
    Antimicrob Agents Chemother; 1996 Mar; 40(3):767-71. PubMed ID: 8851608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of didanosine and drug resistance mutations in infants exposed to zidovudine during gestation or postnatally and treated with didanosine or zidovudine in the first three months of life.
    Kovacs A; Cowles MK; Britto P; Capparelli E; Fowler MG; Moye J; McIntosh K; Rathore MH; Pitt J; Husson RN
    Pediatr Infect Dis J; 2005 Jun; 24(6):503-9. PubMed ID: 15933559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial.
    Musiime V; Kendall L; Bakeera-Kitaka S; Snowden WB; Odongo F; Thomason M; Musoke P; Adkison K; Burger D; Mugyenyi P; Kekitiinwa A; Gibb DM; Walker AS;
    Antivir Ther; 2010; 15(8):1115-24. PubMed ID: 21149918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.